Financial Advantage’s Bristol-Myers Squibb BMY Stock Holding History

Financial Advantage’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$2.96M	Sell	51,049 -33,181	-39%	-$2.03M	4.55%	6
2023 Q2	$5.39M	Buy	84,230 +1,103	+1%	+$74K	4.82%	4
2023 Q1	$5.76M	Buy	83,127 +85	+0.1%	+$6K	5.23%	4
2022 Q4	$5.97M	Sell	83,042 -1,747	-2%	-$132K	5.54%	3
2022 Q3	$6.03M	Buy	84,789 +52	+0.1%	+$3.77K	5.95%	3
2022 Q2	$6.52M	Buy	84,737 +771	+0.9%	+$58.7K	6%	3
2022 Q1	$6.13M	Buy	83,966 +753	+0.9%	+$50.6K	4.96%	4
2021 Q4	$5.19M	Buy	83,213 +2,213	+3%	+$130K	4.28%	6
2021 Q3	$4.79M	Buy	81,000 +806	+1%	+$53.1K	4.16%	5
2021 Q2	$5.36M	Sell	80,194 -1,918	-2%	-$125K	4.58%	5
2021 Q1	$5.18M	Buy	82,112 +772	+0.9%	+$48K	4.48%	5
2020 Q4	$5.04M	Sell	81,340 -5,375	-6%	-$331K	4.67%	5
2020 Q3	$5.23M	Sell	86,715 -28,031	-24%	-$1.69M	4.96%	5
2020 Q2	$6.75M	Sell	114,746 -1,565	-1%	-$93.6K	5.1%	5
2020 Q1	$6.48M	Sell	116,311 -2,434	-2%	-$149K	5.66%	5
2019 Q4	$7.62M	Buy	118,745 +45,144	+61%	+$2.59M	5.22%	6
2019 Q3	$3.73M	Buy	73,601 +487	+0.7%	+$22.9K	2.54%	19
2019 Q2	$3.31M	Buy	73,114 +975	+1%	+$45.4K	2.27%	21
2019 Q1	$3.44M	Buy	+72,139	New	+$3.59M	2.45%	21
2017 Q4	–	Sell	-450	Closed	-$29K	–	42
2017 Q3	$29K	Buy	+450	New	+$26.3K	0.02%	66
2015 Q4	–	Sell	-450	Closed	-$27K	–	43
2015 Q3	$27K	Hold	450	–	–	0.03%	73
2015 Q2	$30K	Hold	450	–	–	0.03%	68
2015 Q1	$29K	Hold	450	–	–	0.03%	69
2014 Q4	$27K	Hold	450	–	–	0.03%	66
2014 Q3	$23K	Hold	450	–	–	0.02%	72
2014 Q2	$22K	Hold	450	–	–	0.02%	74
2014 Q1	$23K	Hold	450	–	–	0.02%	74
2013 Q4	$24K	Hold	450	–	–	0.02%	96
2013 Q3	$21K	Hold	450	–	–	0.02%	92
2013 Q2	$20K	Buy	+450	New	+$19.5K	0.02%	102

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Financial Advantage's BMY Position: Q3 2023 in Review

Financial Advantage reduced its Bristol-Myers Squibb (BMY) stake by 39% in Q3 2023, selling an estimated $2.03M and leaving 51,049 shares worth $2.96M. The position accounts for 4.55% of the portfolio, ranked #6.

Financial Advantage first reported a position in BMY in Q2 2013 and has held it in 30 quarters since. The position peaked at $7.62M in Q4 2019. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.

Financial Advantage held 51,049 shares of Bristol-Myers Squibb worth $2.96M as of Q3 2023.
Financial Advantage sold 33,181 Bristol-Myers Squibb shares in Q3 2023, an estimated $2.03M.
Bristol-Myers Squibb made up 4.55% of Financial Advantage's portfolio in Q3 2023, its #6 holding.
Financial Advantage first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 30 quarters since.
Financial Advantage's Bristol-Myers Squibb position peaked at $7.62M in Q4 2019.
2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.

Based on Financial Advantage's 13F filing for Q3 2023, filed 7 Nov 2023.